top of page
News, Events and Updates
Search
Jun 10, 2016
AAT Presentation
Jun 5, 2016
Anavex Announces Positive Preclinical Results w/ ANAVEX 2-73 in Fragile X — Autism-Related Disorders
May 19, 2016
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
May 17, 2016
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
May 10, 2016
Anavex Reports Fiscal Second Quarter 2016 Financial Results
May 2, 2016
Speaker Session: BIO 2016 International Convention
Apr 7, 2016
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
Apr 5, 2016
33rd Camerino-Cyprus Symposium
Apr 5, 2016
Anavex Annual Stockholders Meeting
Mar 13, 2016
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
Mar 13, 2016
AF710B, a Concomitant Activator of M1 Muscarinic and Sigma-1 Receptors: Possibly Disease-Modifying
27
28
29
30
31
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
